HC Wainwright & Co. Reiterates Buy on Werewolf Therapeutics, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andres Maldonado has reiterated a 'Buy' rating on Werewolf Therapeutics (NASDAQ:HOWL) and maintained a $15 price target.
October 31, 2023 | 3:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Werewolf Therapeutics' stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $15.
The reiteration of a 'Buy' rating and maintained price target by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. This could potentially lead to increased investor confidence and a short-term increase in the stock price of Werewolf Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100